News
ASCO GU 2024, CheckMate 214 trial, nivolumab, ipilimumab, nivolumab plus ipilimumab, renal cell carcinoma (RCC), checkpoint inhibitor combination therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback